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Introduction: Reference intervals (RIs) of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) are age,
assay and population specific. Currently, the age and assay-specific RIs for TSH are not available for children
under two years of age. This study aimed to establish reference intervals for serum concentrations of TSH and
FT4 in healthy children aged 1–24 months as per CLSI C28-A3 guidelines.
Methods: This prospective cross-sectional study was conducted in children from 1 to 24 months visiting the
clinical laboratory for serum vitamin D testing but without any recent illness, hospitalization, medication and
history of maternal thyroid diseases from August 2018 to March 2019 were invited to participate in the study.
Serum TSH and FT4 were measured on ADVIA Centaur (Siemens Diagnostics, US), using chemiluminescence
immunoassay. Kolmogorov–Smirnov test assessed normality of the data and RIs based on central 95% of the
population were established using the non-parametric approach.
Results: After excluding one subject with confirmed congenital hypothyroidism, a total of 131 children were
included in the study. The median (IQR) age of the study subjects was 12 months (11), and majority 78 (59.5%)
were boys. The RIs were established using non-parametric approach as the data was not normally distributed.
Reference interval for TSH was 0.73–4.94 μIU/mL and for FT4 was 0.81–1.51 ng/dl.
Conclusion: We established assay-specific RIs for serum TSH and FT4 in children aged 1–24 months in our
population. The RIs were slightly lower from RIs developed on other platforms in different population.

1. Introduction
Congenital hypothyroidism (CH) occurs in approximately 1: 2,000 to
1: 4,000 newborns worldwide [1]. However, Pakistan’s estimated inci
dence is much higher, approximately 1 in 1600 live births [2]. The CH is
one of the most common preventable causes of mental retardation [3].
With early detection through newborn screening (NBS) and prompt
treatment with levothyroxine, intellectual disability can be prevented
[4].
Screening for CH is performed by dried blood spot screening of
Thyroid Stimulating Hormone (TSH) within 48–72 h of birth. A positive
screening test is confirmed by measuring serum TSH and free thyroxine
(FT4) levels [5]. For a better intellectual outcome of patients with CH,
thyroid hormone concentrations should be normalized rapidly (within
the first two weeks after treatment initiation) and then maintained [6].

According to the American Academy of Pediatrics Guidelines, for
optimal thyroxin replacement, serum TSH and FT4 measurements
should be performed at regular intervals. More frequent monitoring is
recommended when compliance is questioned, abnormal values are
obtained, or dose or medication source has been changed [7].
Appropriate age, population and assay-specific TSH reference in
tervals (RIs) are essential for optimal treatment outcomes. The RIs of
TSH are wider in neonates as compared to infants and other pediatric
age groups, so if one uses the same neonatal RIs to interpret the results of
children older than one month and vice versa, it will lead to under or
over the treatment of the patient, leading to adverse effects and un
necessary repeated testing.
Guidelines by the National Academy of Clinical Biochemistry
recommend that each laboratory determine their age and assay-specific
TSH-RIs to ensure appropriate interpretation [8]. There was a need to
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Fig. 1. Flowchart of subjects included in the study.

establish RIs for our population in children under two years to improve
clinical care. This study was conducted to establish RIs for serum TSH in
healthy children under two years of age, as per the Clinical Laboratory
Standards Institute (CLSI), C28-A3 guidelines. We also compare estab
lished cutoffs with reported reference data [9].

analyzed on ADVIA® Centaur™, Siemens Diagnostics USA using
chemiluminescence immunoassay technique. The ADVIA Centaur TSHUltra (3rd generation) assay’s analytical measurement range was from
0.010 to 150 μIU/mL (1uIU/mL = 1mIU/L), while for FT4 was 0.1–12.0
ng/dl. The TSH assay standardization was traceable to the World Health
Organization (WHO) 3rd International Standard for human TSH (IRP
81/565), so results were not procedure dependent. Three-level quality
control materials were run with each batch of samples for internal
quality control. External proficiency was assured by analyzing samples
from the College of American Pathologists thrice per year, throughout
the study period, and all external proficiency surveys during the study
period were acceptable. The manufacturer provided TSH RIs were for
>2 years to adult age-group only, while the manufacturer provided RI
for FT4 for children of 1–23 months was 0.94–1.44 ng/dl.
The RIs for children aged 1–24 months were established using the
CLSI, C28-A3 guidelines ’Defining, Establishing, and Verifying Refer
ence Intervals in the Clinical Laboratory; Approved Guideline Third
Edition’. These guidelines recommend using a sample size of at least 120
specimens, to obtain both an RI estimate and a 90% confidence interval
for it without making any assumption about the population distribution.
The sample size was kept at 132, after adding an attrition rate of 14%.
Ethical approval was sought and obtained from the institution’s Ethical
Review Committee before the study’s commencement (ERC number:
5255-Pat-ERC-18).

2. Material and methods
A prospective cross-sectional study was conducted at the Section of
Chemical Pathology, Department of Pathology and Laboratory Medi
cine, AKUH Karachi Pakistan after approval from Aga Khan University
Hospital’s Ethics Review Committee. The study has been reported in line
with the STROCSS criteria [10]. This study is registered on ‘Clin
icaltrials.gov’ and the unique Identifying number is NCT04877665.
Healthy children from 1 to 24 months visiting the clinical lab for serum
vitamin D testing from August 2018 to March 2019 were invited to
participate in the study. Their health status was determined by asking
questions related to recent illness, hospitalization, medication and
maternal history of thyroid-related diseases (Appendix 1), after
informed consent from their parents/guardian. Children with recent
abnormal total leucocyte or neutrophil count in the medical record or
positive microbial cultures, history of any diagnosed disease or infec
tion, history of hospitalization during the previous four weeks,
congenital hypothyroidism or transient congenital hypothyroidism,
history of maternal thyroid illness, or any medications with potential
influences on the thyroid function, such as amiodarone, anti-epileptic
drugs, glucocorticoids were excluded, shown in Fig. 1.

2.2. Statistical analysis
The EP evaluator version 10 and SPSS version 21 were used for data
analysis. Kolmogorov–Smirnov test assessed the normality of the data.
The RIs based on central 95% of the population were established using
the nonparametric approach. In the nonparametric method, the refer
ence interval is calculated, making no assumption about the population

2.1. Biochemical analysis
Residual serum samples received for serum vitamin D testing were
utilized to measure serum TSH and FT4. Serum TSH and FT4 were

Table 1
Reference interval for thyroid stimulating hormone and free T4 in children under 2 Years of age (n = 131).
TSH (μIU/mL)

FT4 (ng/dl)

Range

Median

P-value

Lower Limit (95% CI)

Upper Limit (95% CI)

Male (n ¼ 78)
Female (n ¼ 53

0.61–4.95
0.86–6.91

1.87
2.13

0.096

0.67 (0.55–0.81)
0.75 (0.61–0.92)

Both (n ¼ 131)

0.61–6.91

1.94

Male (n ¼ 78)

0.68–1.73

1.09

Female (n ¼ 53)

0.75–1.53

1.09

0.77 (0.70–0.83)

Both (n ¼ 131)

0.68–1.73

1.09

0.81 (0.68–0.84)

4.31 (3.81–4.86)
5.75
4.70–7.03
4.94
4.41–6.91
1.47
1.40–1.54
1.43
1.37–1.50
1.51
1.42–1.73

0.73 (0.61–0.86)
0.878

2

0.80 (0.76–0.84)
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Fig. 2(a). Age-wise distribution of Thyroid Stimulating Hormone levels in study subjects.

Fig. 2 (b). Age-wise distribution of Free T4 levels in study subjects.

distribution shape. The median age of subjects, TSH and FT4 levels were
calculated. For assessing differences in the male and female gender,
Students’ t’ test was applied, taking p-value <0.050 as significant.
Spearman’s test computed the correlation between age, TSH and FT4
levels.

Table 2
Distribution of Thyroid Stimulating Hormone and Free T4 in different age
groups (n = 131).

3. Results
A total of 132 children were included in the study; one subject with
confirmed congenital hypothyroidism (CH) was excluded from the
study, shown in Fig. 1. The TSH and FT4 values of 131 subjects were
included to establish the RIs. The median (IQR) age of the study subjects
was 12 (11) months, and 78 (59.5%) were male. The median (95% in
tervals) of serum TSH and free T4 were 1.94 (0.61–6.91) μIU/L and 1.09
(0.68–1.73) ng/dL respectively.
The data was not normally distributed, so the non-parametric
approach was applied to establish RIs. Reference interval based on
central 95% of the population for TSH is 0.73–4.94 μIU/mL and for FT4
is 0.81–1.51 ng/dL. The RIs for Male and female were not significantly
different for both TSH (p-value 0.096) and FT4 (p-value 0.878),
(Table 1).

-

<6 months

7–12 months

13–24 months

p value

n
TSH (uIU/ml)
FT4 (ng/dl)

37
2.72 ± 1.3
1.19 ± 0.2

34
2.12 ± 1.06
1.05 ± 0.14

60
1.88 ± 0.88
1.06 ± 0.14

–
0.001
<0.001

Both TSH (p value 0.000, r = − 0.339) and FT4 (p value 0.006, r =
− 0.239) levels significantly correlated with age, the levels decreasing
with increasing age, Fig. 2(a) and (b).
Subjects were divided into three age groups, Group I; <6 months,
group II; 7–12 months and group III; 13–24 months. The mean difference
between TSH and FT4 levels between these age groups was statistically
significantly (p-value 0.001 and p-value <0.001) respectively (Table 2).
4. Discussion
CH is one of the most common preventable causes of mental retar
dation and satisfies all the criteria for being included in an NBS program
3
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Table 3
The RIs determined by Kapelri et al. (12), Hubner et al. (13) and Loh et al. (14) using Advia Centaur Immunoassay analyzer.
Study

Our Study

Kapelari et al.

Hubner et al.

Tze Ping Loh et al.

Country

Pakistan

Austria

Germany

Singapore

Analyzer

Advia Centaur

Advia Centaur

Advia Centaur

Age
FT4 (ng/dl)
TSH (μIU/ml)

1–24 Months
0.79–1.34
0.733 4.945

1m–12 m
0.92–1.74
1.30–7.09

1y-2y
0.92–1.61
1.0–5.42

1m-1y
0.88–1.62
0.30–5.88

[11]. After a CH diagnosis, all children should be treated and frequently
monitored using serum TSH and FT4. For accurate monitoring, appro
priate RIs must be used for reporting the patient’s results. The RIs of TSH
is affected by age, gender, population, iodine intake and assay used [8].
This study was conducted to establish assay and population-specific
RIs for children aged 1–24 months, as RIs for this age group were not
available. The RIs determined by the present study for TSH and FT4
were 0.73–4.94 μIU/mL and 0.81–1.51 ng/dl, respectively. No studies
have reported assay and population-specific RIs for the Pakistani, Indian
or even South Asian population to the best of our knowledge. However,
the clinical practice guidelines for screening, diagnosis and management
of CH by the Indian Society for Pediatric and Adolescent Endocrinology
has recommended the RIs determined by Lem AJ et al. in a European
population of Netherlands [6,12]. The RIs determined by Lem AJ et al.
for 1–3 months, 3–12 months, 1–5 years for TSH were 0.58–5.57 mIU/L,
0.57–5.54 mIU/L, 0.56–5.41 mIU/L and FT4 were 1.04–3.4 ng/dl,
1.1–2.4 ng/dl, 1.1–2 ng/dl respectively. These RIs are slightly wider
than the RIs established in our population, the difference could have
been due to a different assaying platform utilized, i.e. Advia Centaur
immunoassay analyzer (Siemens Diagnostics) used in current study
while Vitros ECI immunoassay analyzer (Ortho Diagnostics) used by
Lem AJ et al. When comparing with RIs developed on a similar platform
as used in the present study, i.e. Advia Centaur immunoassay analyzer
(Siemens Diagnostics), but different population we observed that the RIs
for our population were slightly lower as compared to Caucasians and
Asians shown in Table 3 [13–15]. Loh TP et al. established TSH RIs in
Asian children, including 59% Chinese and 13% Indians using Advia
Centaur immunoassay in 82% of the subjects [15].
The trends of the reference values obtained from this study showed
slight differences from those obtained from the other studies, which
might be explained by different analytical assays, different tools used for
statistical analysis, differences in ethnicity, population or geographic
derived covariates such as lifestyle, salt iodination, and nutrition. These
findings further endorse that there was a dire need to develop assayspecific RIs for our population. The RIs established in subjects from
the same geographic area, using the same analyzer used in routine work,
is definitively better.
We observed no significant difference in TSH or FT4 RIs between
male and female in the present study. However, RIs significantly
correlated with age, i.e. decreasing RIs with increasing age, Table 2.
Similar findings were reported by Kratzsch J. et al. which assessed the
association between TSH, age, BMI, Number of blood leucocytes, gender
and observed that only age was a relevant predictor of TSH variation
with 8% [16]. Therefore, these findings suggest that the establishment of
age-dependent reference intervals is mandatory for TSH and larger,
prospective studies should be performed to address these findings.
This is the first study from Pakistan reporting the RIs for TSH and FT4
for children aged 1–24 months using the Advia® Centaur™ assay. One
of the strengths of this study was the prospective study design. Col
lecting pediatric healthy subjects samples is especially difficult, and
most of the studies reported in the literature have established TSH and
FT4 RIs for pediatric age groups using retrospective data analysis. Our
study presents some limitations, including small sample size, nonpartitioning of the data into smaller age groups, and due to limited
availability of funds thyroid, antibody testing of mother and child could

Advia Centaur and Ortho Vitros 5600
1y-5y
0.88–1.47
1.0–5.42

2m-4y
–
0.74–5.68

not be performed. A more extensive prospective study needs to be
planned with further age categorization for a more generalizable data.
5. Conclusion
We established assay-specific RIs for serum TSH and FT4 in children
aged 1–24 months in our population. The RIs developed differed slightly
from RIs developed using other platforms in different population. The
TSH and FT4 were significantly associated with age, requiring that
validated RIs developed for our population should be used for assessing
TSH and FT4 results in children under two years of age. However same
RIs of TSH and FT4 can be used for both male and female children.
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